---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-000728"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T20:40:12.186578+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Alnylam Q1 product rev $276M (+48% YoY); ALN-APP CNS data positive; FY guidance reaffirmed

## Summary
- Q1 net product revenue $276M (+48% YoY); AMVUTTRA $102M and ONPATTRO $102M drove TTR growth of 49%.
- GAAP net loss $174M ($1.40/share); non-GAAP net loss $132M ($1.06/share). FY23 revenue guidance $1.2B-$1.285B reaffirmed.
- Positive interim Phase 1 data for ALN-APP in early-onset Alzheimer's: first human RNAi CNS gene silencing demonstrated.
- 18-month APOLLO-B data submitted to FDA for ONPATTRO in cardiomyopathy; KARDIA-1 (zilebesiran) topline expected mid-2023.

## SEC filing metadata
- accession: 0001157523-23-000728
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000115752323000728/0001157523-23-000728-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000115752323000728/a53393280.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-000728
- JSON: https://secwatch.observer/filing/0001157523-23-000728.json
- Plain text: https://secwatch.observer/filing/0001157523-23-000728.txt

## Key facts
- Earnings Releases
  ALNYLAM PHARMACEUTICALS, INC. reported the first quarter ended March 31, 2023 results: revenue $276 Million. Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $276 Million
  - Guidance: reaffirmed
  - Result: reported results
  source text: − Achieved First Quarter 2023 Global Net Product Revenues of $276 Million, Representing 48% Year-Over-Year Growth Compared to Q1 2022 –
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178670/000115752323000728/0001157523-23-000728-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.